Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study

被引:30
作者
Ciccaglione, Antonio Francesco [1 ]
Di Giulio, Mara [2 ]
Di Lodovico, Silvia [2 ]
Di Campli, Emanuela [2 ]
Cellini, Luigina [2 ]
Marzio, Leonardo [1 ]
机构
[1] Univ G dAnnunzio, Pescara Civ Hosp, Digest Sci Unit, Via Fonte Romana 8, I-65124 Pescara, Italy
[2] Univ G dAnnunzio, Dept Pharm, Via Vestini, I-66013 Chieti, Italy
关键词
RECOMBINANT HUMAN LACTOFERRIN; ANTIBIOTIC-RESISTANCE; GENETIC-VARIABILITY; ERADICATION; CLARITHROMYCIN; PREVALENCE; PROTEINS; REGIMENS; STOMACH; BLIND;
D O I
10.1093/jac/dky510
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as the first-line treatment for H. pylori infection. Methods The bovine lactoferrin antimicrobial/antivirulence effect was analysed in vitro by MIC/MBC determination and twitching motility against six clinical H. pylori strains and a reference strain. The synergism was evaluated using the chequerboard assay. The prospective therapeutic trial was carried out on two separate patient groups, one treated with esomeprazole/amoxicillin/levofloxacin and the other with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin. Treatment outcome was determined with the [C-13]urea breath test. Results In vitro, bovine lactoferrin inhibited the growth of 50% of strains at 10mg/mL and expressed 50% bactericidal effect at 40mg/mL. The combination of levofloxacin and bovine lactoferrin displayed a synergistic effect for all strains, with the best MIC reduction of 16- and 32-fold for levofloxacin and bovine lactoferrin, respectively. Bovine lactoferrin at one-fourth MIC reduced microbial motility significantly for all strains studied. In the in vivo study, 6 of 24 patients recruited had treatment failure recorded with esomeprazole/amoxicillin/levofloxacin (75% success, 95% CI 57.68%-92.32%), and in the group with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin, 2 out of 53 patients recruited had failure recorded (96.07% success, 95% CI 90.62%-101.38%). Conclusions Bovine lactoferrin can be considered a novel potentiator for restoring susceptibility in resistant H. pylori strains. Bovine lactoferrin added to a triple therapy in first-line treatment potentiates the therapeutic effect.
引用
收藏
页码:1069 / 1077
页数:9
相关论文
共 58 条
[1]  
Aldana LP, 2002, HELICOBACTER, V7, P306
[2]  
[Anonymous], 2016, Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, V3rd
[3]  
BALDWIN DA, 1984, J BIOL CHEM, V259, P3391
[4]   Helicobacter pylori and Gastric Cancer [J].
Bornschein, Jan ;
Malfertheiner, Peter .
DIGESTIVE DISEASES, 2014, 32 (03) :249-264
[5]   Lactoferrin: milking ulcers? [J].
Borody, TJ ;
Ashman, O .
DIGESTIVE AND LIVER DISEASE, 2003, 35 (10) :691-693
[6]  
Boyanova L, 2010, EXPERT REV ANTI-INFE, V8, P59, DOI [10.1586/eri.09.113, 10.1586/ERI.09.113]
[7]   Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? [J].
Brown, David .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (12) :821-832
[8]   Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care:: a multicentre, randomized trial [J].
Calvet, X ;
López-Lorente, MT ;
Cubells, MJ ;
Baré, M ;
Gálvez, E ;
Molina, E .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :781-786
[9]   Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy [J].
Cellini, L ;
Grande, R ;
Di Campli, E ;
Di Bartolomeo, S ;
Capodicasa, S ;
Marzio, L .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (03) :280-287
[10]   Inhibition of Helicobacter pylori by garlic extract (Allium sativum) [J].
Cellini, L ;
DiCampli, E ;
Masulli, M ;
DiBartolomeo, S ;
Allocati, N .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1996, 13 (04) :273-277